BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clinical Chemistry and Laboratory Medicine (CCLM) 2015;53. [DOI: 10.1515/cclm-2015-0024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Jepson RE, Cardwell JM, Cortellini S, Holm L, Stevens K, Walker D. Cutaneous and Renal Glomerular Vasculopathy: What Do We Know so Far? Vet Clin North Am Small Anim Pract 2019;49:745-62. [PMID: 30961997 DOI: 10.1016/j.cvsm.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Edens C, Rodrigues BC, Lacerda MI, Dos Santos FC, De Jesús GR, De Jesús NR, Levy RA, Leatherwood C, Mandel J, Bermas B. Challenging cases in rheumatic pregnancies. Rheumatology (Oxford) 2018;57:v18-25. [PMID: 30137591 DOI: 10.1093/rheumatology/key172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin 2020;36:333-56. [PMID: 32172817 DOI: 10.1016/j.ccc.2019.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Sampedro López A, Domínguez Moro B, Baltar Martin JM, Garcia Monteavaro C, Barbón García JJ. Ocular involvement in atypical haemolytic uraemic syndrome. Arch Soc Esp Oftalmol 2017;92:594-7. [PMID: 28347544 DOI: 10.1016/j.oftal.2017.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
6 Nanjappa S, Singh V, Uttamchandani S, Pabbathi S. Thrombotic Microangiopathy in a Patient Treated With Gemcitabine. Cancer Control 2017;24:54-6. [PMID: 28178713 DOI: 10.1177/107327481702400108] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Alobaidi S, AlDabbagh A, Alamoudi A, Almowarey M, Akl A. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene. CEN Case Rep 2019;8:139-43. [PMID: 30715674 DOI: 10.1007/s13730-019-00383-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 2018;177:311-8. [PMID: 29288280 DOI: 10.1007/s00431-017-3077-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
11 Lipiec K, Adamczyk P, Świętochowska E, Ziora K, Szczepańska M. Angiotensinogen and Interleukin-18 as Markers of Chronic Kidney Damage in Children With a History of Hemolytic Uremic Syndrome. Physiol Res. [DOI: 10.33549/physiolres.933340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 De Leonardis F, Koronica R, Daniele RM, Santoro N. Thrombotic Thrombocytopenic Purpura in a Child Treated for Acute Lymphoblastic Leukemia: Case Report and Review of Literature. J Pediatr Hematol Oncol 2018;40:558-9. [PMID: 29219891 DOI: 10.1097/MPH.0000000000001050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]